|
End-of-day quote
Nasdaq
2026-11-03
|
5-day change | 1st Jan Change | ||
| 28.15 USD | -32.85% |
|
-31.27% | -43.36% |
| 11-02 | Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from S&P Composite 1500 | CI |
| 11-02 | Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from S&P 600 | CI |
Company Valuation: Supernus Pharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,551 | 1,928 | 1,581 | 1,997 | 2,850 | 1,639 | - | - |
| Change | - | 24.34% | -18% | 26.29% | 42.72% | -42.47% | - | - |
| Enterprise Value (EV) | 1,551 | 1,928 | 1,581 | 1,997 | 2,850 | 1,639 | 1,639 | 1,639 |
| Change | - | 24.34% | -18% | 26.29% | 42.72% | -42.47% | 0% | 0% |
| P/E | 29.8x | 34.3x | 1,447x | 27.4x | -73.1x | -188x | 14.7x | 8.45x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 5.6x | -14.8x | 0x | 0x | 2.4x | -0x | 0.1x |
| Capitalization / Revenue | 2.67x | 2.89x | 2.6x | 3.02x | 3.96x | 1.85x | 1.61x | 1.38x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.85x | 1.61x | 1.38x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 9.55x | 6.76x | 5.01x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 10.8x | 9.88x | 5.01x |
| FCF Yield | 8.07% | 6.04% | 6.99% | 8.58% | 1.61% | 9.24% | 10.1% | 19.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.98 | 1.04 | 0.02 | 1.32 | -0.68 | -0.15 | 1.917 | 3.33 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 579.8 | 667.2 | 607.5 | 661.8 | 719 | 884.4 | 1,020 | 1,184 |
| EBITDA | 118.6 | 128.8 | 97.3 | 159.6 | 250.3 | - | - | - |
| EBIT 1 | 86.03 | 46.12 | 125.1 | 183.7 | 158.7 | 171.7 | 242.5 | 327.4 |
| Net income 1 | 53.42 | 60.71 | 1.316 | 73.86 | -38.55 | -8.215 | 112.7 | 194.8 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 29.16 | 35.67 | 28.94 | 36.16 | 49.70 | 28.15 | 28.15 | 28.15 |
| Nbr of stocks (in thousands) | 53,181 | 54,058 | 54,633 | 55,219 | 57,339 | 58,236 | - | - |
| Announcement Date | 4/13/22 | 2/28/23 | 2/27/24 | 2/25/25 | 2/24/26 | - | - | - |
1USD in Million2USD
Estimates
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SUPN Stock
- Valuation Supernus Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
